Sinopharm Modern Subsidiary Gains Approval for Vonoprazan Fumarate API
Sinopharm Modern announced that its wholly-owned grand subsidiary, Sinopharm Jiangsu Weiqida, has received an approval notice for the marketing application of the chemical active pharmaceutical ingredient (API) vonoprazan fumarate, issued by the National Medical Products Administration (NMPA). The API is primarily used for the treatment of reflux esophagitis and Helicobacter pylori infection.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceutical Chemicals, with intensity 30/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.